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ABSTRACT
Out of 732 renal biopsies performed from 1988 to 1995 in Queen Elizabeth Hospital, 65 patients
(8.9%, 43 male, 22 female) were diagnosed to have IgM mesangial nephropathy (IgMN). The mean
age of the patients was 35 ±2 years. The clinical manifestations and progression of IgMN were
studied in 39 of these 65 patients. The initial manifestations of the disease included nephrotic
syndrome in 18 patients (46%), proteinuria and hematuria in nine patients (23%), non-nephrotic
proteinuria in 11 patients (28%) and isolated hematuria in one patient (3%). The nephrotic syndrome
was steroid-responsive in 16 of the 18 patients (89%) and six of them (33%) were steroid dependent.
Two of the 11 (18%) patients in the isolated proteinuria group had a progressive deterioration in
renal function. The renal function of the patients presented as hematuria with or without proteinuria
remained stable during the follow-up period. We concluded that IgMN appeared to be a heterogeneous
disease. Further studies on the classification and treatment are warranted in this group of patients.
Key words: Glomerulonephritis, Proteinuria, Renal failure
 !
 NVUU NVVR !"#$%&'()* TPO !"#$% SRE ! UKVB 
QP ! OO F !" fÖj !"EfÖjkF !"#$%&'( PR=±O !"#
SR !"PV !"#$%&'()*+,-./0)"#$%123.4567NUEQSBF
 !" #$%EOPBF !"#$"%&'(NNEOUBF !"#$%&EPBFNUEUVBF
 !"#$%&'(NS !"#$%&'()EPPBF !"#$NN !"#$%&
 !"#$%&'()*+,-%./0./123/456789&'(:;<=+>?@AB
fÖj !"#$%&'() *"+,-./0123456789:&;<=+
O R I G I N A L
A R T I C L E
Correspondence: Dr. Kim-Ming WONG, Renal Unit, Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon,
Hong Kong. Fax: (852) 2781 1766, E-mail: wongfkm@hotmail.com
ournal f Nephrology
2000;2(1):23-26.
Hong Kong Journal of Nephrology, April 2000
thin and delicate. Ultrastructural examination discloses
the presence of typical electron dense mesangial deposits
in approximately 50% of the biopsies (1). The remaining
patients displayed ill-defined deposits or do not exhibit
any recognizable ones. In patients with heavy proteinuria,
effacement of epithelial foot processes was found (1,2,
4).
Since the report of Cohen and Bhasin, there has been
considerable debate on the existence of this clinical entity
and its prognostic significance. The response to steroid
INTRODUCTION
IgM mesangial nephropathy (IgMN) was first described
by Cohen et al (1) and Bhasin et al (2) in 1978. The
glomerular lesion of IgMN is defined by i ts
immunopathologic features (3): the presence of IgM as
the sole or dominant immunoglobulin in glomerular
mesangial regions in a diffuse and generalized
distribution. The light microscopic manifestations are
those of mild to moderate expansion of the mesangial
regions, sometimes associated with increase in mesangial
cellularity. Capillary walls and basement membrane are
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therapy and the long-term prognosis of this condition
varied from studies to studies (4-9). Some investigators
showed that patients with IgMN had a higher incidence
of steroid dependency and responded partially to
cyclophosphamide (5). Other investigators found that
there was no difference between the groups with or
without IgM deposits (6-8). Herein we studied
retrospectively the prevalence, the different clinical
manifestations, the progression and prognosis of IgMN
in our locality.
METHODS
We reviewed all the renal biopsies done between January
1988 to June 1995 in our hospital retrospectively. The
indications of renal biopsy were unexplained renal
dysfunction and/or proteinuria more than 1 g/day and
isolated hematuria. The renal biopsy specimens were
e x a m i n e d  b y  l i g h t - m i c r o s c o p i c  ( L M )  a n d
immunofluorescence (IF) methods using standard
techniques and electron microscopy. Paraffin sections
for LM were stained by the hematoxylin-eosin (HE),
periodic acid-Schiff (PAS), Masson's trichrome and
periodic acid-silver methenamine methods. Direct IF
studies were carried out using monospecific antisera
against the heavy chains of human IgG, IgA and IgM
and against C3, C4, C1q and fibrinogen. Patients who
were diagnosed to have IgM nephropathy were treated
initially with prednisolone 30 mg/day to 40 mg/day, and
received treatment for at least 4 months. Patients were
classified as steroid responsive if there was complete
remission of proteinuria during treatment and had
persistent remission for at least 2 months after
termination of treatment. Patients were classified as
steroid-dependent if they had complete remission during
steroid therapy but recurrence when the dosage was
reduced below a critical level or relapse within 2 months
after discontinuation of therapy. They were classified as
steroid resistant if they had no remission of proteinuria
after 4 months of therapy. The clinical progression of
the renal disease and the response to treatment were
analyzed.
RESULTS
All together, there were 732 biopsies performed in the
study period. Sixty-five patients (8.9%) were diagnosed
to have IgMN. There were 43 males and 22 females and
the mean age was 35 ±2 years. Twenty-six patients
defaulted follow-up, making only 39 patients available
for the study of the progress of the disease. Of the 39
patients, 18 (46%) presented as nephrotic syndrome, 11
(28%) presented as isolated proteinuria, nine (23%)
presented as mixed proteinuria and hematuria and one
(3%) as isolated hematuria (Table 1).
Table 1.  Clinical data on patients with IgMN at presentation.
Clinical manifestation NS PU PUH H All patients
Number of patients 18 11 9 1 39
Males/Females 15/3 9/2 3/6 1/0 28/11
Mean age (years) 26 ±10 42 ±16 44 ±11 30 35 ±2
Mean serum creatinine (µmol/L) 99 ±18 117 ±63 88 ±26 76 100.9
Mean proteinuria (g/day) 12.6 ±7 1.9 ±1.5 2.2 ±1.7  0.05 6.9
Median % of sclerosed 0 25 5  0
Glomeruli on biopsy (0) (0-40) (0-20)
NS = Nephrotic syndrome; PU = Proteinuria; PUH = Proteinuria with hematuria; H = Hematuria
Table 2.  Clinical progress of patients with IgMN at last follow-up.
Clinical manifestation NS PU PUH H All patients
Number of patients 18 11 9 1 39
Median follow-up period (months) 24 31 27 29 25
Renal function
   Initially normal 16/18 5/11 8/9 1/1 30/39
   Stable 16/18 9/11 9/9 1/1 36/39
   Deteriorate 2/18 2/11 0/9 0/1 4/39
Proteinuria
   Stable 2/18 4/11 4/9 1/1 10/39
   Increase 0/18 4/11 3/9 0/1 7/39
   Decrease/remission 16/18 2/11 2/9 0/1 20/39
NS = nephrotic syndrome; PU = Proteinuria; PUH = Proteinuria with hematuria; H = Hematuria
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The clinical progress of these 39 patients was depicted
in table 2. Of the 18 patients with nephrotic syndrome,
16 (89%) were steroid responsive and 6 (33%) were
steroid dependent. After a median follow-up period of
24 months, this group of nephrotic patients had stable
renal function and normal blood pressure. Of the 11
patients with isolated proteinuria, six developed
hypertension and four had impaired renal function after
a median follow-up period of 31 months. Two of them
had progressive deterioration in renal function while two
other patients had spontaneous remission. For the mixed
hematuria and proteinuria group, only one of the nine
patients had mild hypertension after a median follow-up
period of 27 months. One patient, who had a mildly
impaired renal function at presentation, remained stable
during the follow-up period. The patient with isolated
hematuria had normal renal function during the follow-
up period of 29 months.
DISCUSSION
IgMN is a glomerular disease defined by its
immunopathologic features: the presence of IgM as the
sole or dominant immunoglobulin deposited in the
glomerular mesangial regions in a diffuse and generalized
manner (3). Patients usually presented with nephrotic
syndrome (3). However, they can also present with
proteinuria and hematuria, isolated proteinuria and
isolated hematuria (1,5,10). In a case series from Cohen
(1,11), out of 29 patients suffering from IgMN, 23 (79%)
had heavy proteinuria (greater than 3 g/day); nine had
both proteinuria and microscopic hematuria, and
six (20.6%) had isolated hematuria. In our series, most
of our patients presented as nephrotic syndrome (46%).
However, far fewer patients presented as isolated
hematuria (3%) as compared with other studies. The
discrepancy is likely related to sampling bias due to the
difference in the indications of renal biopsy. In our center,
we would not perform renal biopsy routinely for patients
with isolated hematuria. In some other centers, renal
biopsy would be done in all patients suspected of
suffering from glomerular disease provided that no
contraindications were present. The prevalence of
patients with IgMN presented with isolated hematuria
could be as high as 20% in these centers (12).
The existence of IgMN as a separate clinical entity and
its clinical prognostic significance has always been a
subject of controversy. Apparent transitions from
minimal change disease to IgMN and from IgMN to focal
segmental glomerulosclerosis in subsequent biopsy
specimens have been reported (15-18). One hypothesis
is that minimal change disease, IgMN and focal, and
segmental glomerulosclerosis are not separate entities
but simply represent a spectrum of disease that begins
with minimal change and ends in focal sclerosis (10).
An alternate view is that minimal change disease, IgMN
and focal, and segmental glomerulosclerosis are three
separate entities but having overlapping microscopic
appearance (10). Evidence to support the consideration
of IgMN as a different clinical entity includes the
proposed difference in the pathogenesis of the disease
(focal segmental glomerulosclerosis and minimal change
disease are disorders of visceral epithelium while
mesangial proliferative disease is a disorder of the
mesangium); the presence of IgM deposit in the
mesangium; and the differences in the clinical response
to steroid therapy and clinical course from minimal
change disease (11).
The nephrotic syndrome in IgMN was found to be
corticosteroid resistant in 20% to 50% of patients (5,
12). Higher proportions of patients were steroid
dependent (60 % vs 14%) and had poor response to
cyclophosphamide (46% vs 100% were cyclopho-
sphamide responsive) when compared with patients with
minimal change disease (5,11). In our series, a high
proportion of patients were steroid responsive (89%) but
33 % of the responders were steroid dependent. The
steroid responsiveness of our patients is apparently not
as satisfactory as those groups of patients with minimal
change disease. Whether there is any correlation between
the degree of mesangial hypercellularity and the clinical
course and outcome is still a subject of controversy.
While Allen et  al  (13) found that  mesangial
hypercellularity was associated with frequent relapse and
unfavorable course, Cohen et al (11) could not see such
a correlation. Hsu et al (14) in their series of 41 patients
with IgM nephropathy pointed out that patients whose
biopsy specimens were consistent with minimal change
nephrotic syndrome had most favorable clinical course.
From our experience, more patients in the isolated
proteinuria group had impaired renal function at the time
of diagnosis. Two (10%) patients in this group also
showed progressive deterioration in their renal function
during the follow-up period while the renal function of
the patients in all other groups remained stable. There
have been several reports of cases with IgMN in which
a histologic transformation from minimal change or
mesangia l  p ro l i fe ra t ion  to  foca l  segmenta l
glomerulosclerosis had taken place (12,16-18). Usually
these were cases that had poor response to therapy,
progressive increase in proteinuria and deterioration in
renal function. Cohen (3) and Border (10) suggested that
the focal sclerosis appearance represented the late stage
of mesangial proliferative glomerulonephritis.
Border (10) proposed that at the beginning of mesangial
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injury (glomerulonephritis), the resting mesangial cells
appeared normal or to have minimal changes. After
stimulation, the mesangial cells proliferated and
increased the synthesis of mesangial matrix, which could
accumulate and cause glomerulosclerosis. The difference
in microscopic appearance represented the different
stages of the disease and timing of the biopsy. Generally,
patients who exhibited diffuse mesangial expansion and
hypercellularity with prominent diffuse mesangial IgM
deposition in the renal biopsy had a more unfavorable
outcome (15).
Recent investigations found that mesangial cells can be
stimulated to transform into cells resembling monocytes
and macrophages and produce cytokines for cell
proliferation and matrix expansion, for example, IL 1,
IL 6, platelet derived growth factor, transforming growth
factors ß (10,19,20). Such transformation can explain
why immunologic or other stimuli can injure glomeruli
by stimulating the mesangium to start a cycle of perpetual
cell proliferation and matrix expansion that lead to
sclerosis (10). This provides an insight on the possible
pathogenesis of mesangial proliferative glomerulo-
nephritis. Differences in the pathogenic mechanism
should separate IgMN from idiopathic focal segmental
g l o m e r u l o s c l e r o s i s  a n d  m i n i m a l  c h a n g e
glomerulonephritis. This is further supported by the
differences in their clinical response to steroid therapy
and the clinical course of the disease.
One patient with isolated hematuria was found to have
the most favorable prognosis (3,10,11). This only patient
showed a normal and stable renal function during the 29
months follow-up period. It seems that isolated hematuria
represents a favorable clinical feature. It is possible that
there are two unrelated disorders with initially rather
similar histological pictures (12). One type usually
associates with the nephrotic syndrome and shows a
tendency to morphological change and development of
impaired renal function. The other type manifests as
hematuria with or without proteinuria and the overall
clinical course is usually more favorable (12).
CONCLUSIONS
IgMN represents a different pathological-clinical entity
from minimal change disease and focal segmental
glomerulosclerosis. Nephrotic syndrome is the
commonest manifestation in our series. In the group of
patients presented with nephrotic syndrome, most of
them were steroid responsive but a high percentage of
them were steroid dependent. The patients in the mixed
proteinuria and hematuria group appeared to have better
prognosis than patients with isolated proteinuria. IgMN
itself may represent two unrelated disorders with different
long-term prognosis .  Further  s tudies  on the
pathophysiology of the disease, the different
presentations of the disorder, the clinical course and
response to treatment are warranted.
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